



# COVID-19 Provider Update

Wednesday, January 26, 2022



# Population Coverage: As of January 17th

Age Range	% of Population	CT Population	At least one dose		Fully vaccinated		Additional dose Received	
			Number	%	Number	%	Number	%
All ages	100.0%	3,565,287	2,943,928	82.6%	2,573,422	72.2%	1,201,674	33.7%
5+	95.0%	3,383,577	2,943,692	87.0%	2,573,296	76.1%	1,201,661	35.5%
12+	87.0%	3,105,947	2,828,897	91.1%	2,489,092	80.1%	1,201,490	38.7%
16+	82.0%	2,929,347	2,692,673	91.9%	2,367,495	80.8%	1,185,430	40.5%
18+	80.0%	2,837,847	2,615,119	92.2%	2,297,568	81.0%	1,163,797	41.0%
35+	57.0%	2,047,745	1,955,621	95.5%	1,745,389	85.2%	986,351	48.2%
45+	45.0%	1,620,604	1,564,306	96.5%	1,404,650	86.7%	846,433	52.2%
55+	32.0%	1,143,699	1,138,458	99.5%	1,022,287	89.4%	658,826	57.6%
65+	18.0%	630,244	637,709	100.0%	568,668	90.2%	392,629	62.3%
75+	8.0%	277,425	271,533	97.9%	241,452	87.0%	163,510	58.9%

Data as reported to CT DPH Immunization Information System (IIS) CT WiZ.

All ages estimate includes 236 people with unknown age

Additional dose includes individuals who have had at least one dose after completion of the a primary COVID-19 vaccine series



# Age coverage: Specific age groups

Doses Reported by 1/17/2022

Age Range	% of Population	CT Population	At least one dose		Fully vaccinated		Additional dose Received	
			Number	%	Number	%	Number	%
<5	5.0%	181,710	0	0.0%	0	0.0%	0	0.0%
5-11	8.0%	277,630	114,795	41.3%	84,204	30.3%	171	0.1%
12-15	5.0%	176,600	136,224	77.1%	121,597	68.9%	16,060	9.1%
16-17	3.0%	91,500	77,554	84.8%	69,927	76.4%	21,633	23.6%
18-24	10.0%	342,073	275,573	80.6%	226,297	66.2%	70,742	20.7%
25-34	13.0%	448,029	383,925	85.7%	325,882	72.7%	106,704	23.8%
35-44	12.0%	427,141	391,315	91.6%	340,739	79.8%	139,918	32.8%
45-54	13.0%	476,905	425,848	89.3%	382,363	80.2%	187,607	39.3%
55-64	14.0%	513,455	500,749	97.5%	453,619	88.3%	266,197	51.8%
65-74	10.0%	352,819	366,176	100.0%	327,216	92.7%	229,119	64.9%
75-84	5.0%	186,095	191,786	100.0%	170,761	91.8%	120,264	64.6%
85+	3.0%	91,330	79,747	87.3%	70,691	77.4%	43,246	47.4%
<b>Grand Total</b>		<b>3,565,287</b>	<b>2,943,692</b>	<b>82.5%</b>	<b>2,573,296</b>	<b>72.1%</b>	<b>1,201,661</b>	<b>33.7%</b>

\*At least one dose includes individuals who have received one dose of Pfizer, Moderna, or J&J

\*\*Fully vaccinated includes individuals who received one dose of J&J, two doses of Moderna, or two doses of Pfizer.

\*\*\*Additional dose includes individuals who have had at least one dose after completion of the a primary COVID-19 vaccine series

\*\*\*\*236 people with age missing are exclude from this table



# Vaccination After Infection

CDC recommends COVID-19 vaccination for all people with prior SARS-CoV-2 infection.

**Guidance for people with a current infection:** Defer vaccination of people with known current SARS-CoV-2 infection until the person has recovered from acute illness (if the person has symptoms) and until [criteria](#) have been met for them to discontinue isolation.




You do not need to wait 90 days after COVID-19 infection to vaccinate.

# Vaccination of Immunocompromised Individuals

- [Immunocompromised individuals](#) who received mRNA vaccines became eligible for an [additional primary dose](#) of an mRNA vaccine on August 13, 2021.
- On January 13, 2022, these individuals became eligible for a booster dose of COVID-19 vaccine; mRNA vaccines are the preferred at this time.
  - Note: this means some people are eligible for, and recommended to receive, four doses of COVID-19 vaccine depending on the product used to complete their primary series.
  - If your scheduling platform includes vaccine history logic, ensure that it is updated to reflect this group.
  - If you provide care for immunocompromised individuals, please send a message to those patients informing them that they are recommended a booster dose starting at 5 months after completion of the primary series/third dose of an mRNA vaccine.

**Do not turn away immunocompromised individuals seeking a booster dose.**

# Pfizer Kids < 5 Update

Description	Formulations			Potential new formulation**
	<i>Dilute Prior to Use</i>	<i>Do Not Dilute</i>	<i>Dilute Prior to Use</i>	<i>Dilute Prior to Use</i>
Age Group	12 years and older	12 years and older	5 to <12 years*	TBD
Vial Cap Color	<b>PURPLE</b>  	<b>GRAY (Coming soon)</b>  	<b>ORANGE</b>  	<b>Maroon Cap (pre-EUA)</b>
Dose	30 mcg	30 mcg	10 mcg	3 mcg
Injection Volume	0.3 mL	0.3 mL	0.2 mL	0.2 mL
Fill Volume (before dilution)	0.45 mL	2.25 mL	1.3 mL	?
Amount of Diluent* Needed per Vial	1.8 mL	<b>NO DILUTION</b>	1.3 mL	?
Doses per Vial	6 doses per vial (after dilution)	6 doses per vial	10 doses per vial (after dilution)	10 doses per vial (after dilution)
<b>Storage Conditions</b>				
ULT Freezer (-90°C to -60°C)	9 months	9 months	9 months	9 months
Freezer (-25°C to -15°C)	2 weeks	N/A	N/A	N/A
Refrigerator (2°C to 8°C)	1 month	10 weeks	10 weeks	10 weeks

\*Diluent: 0.9% sterile Sodium Chloride Injection, USP (non-bacteriostatic; DO NOT USE OTHER DILUENTS

\*\* <https://www.cdc.gov/vaccines/programs/iis/COVID-19-related-codes.html>

# CDC Morbidity and Mortality Weekly Report

Stay informed about COVID-19

Read the latest reports from **MMWR**

During the emergence of the Omicron variant, being up to date with **COVID-19 vaccines** provided protection against infection\*

Adults who were unvaccinated had **5x higher risk of infection** compared with adults who were fully vaccinated with a booster

bit.ly/mm7104

\*25 U.S. jurisdictions, December 2021

- Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. Link [here](#).
- COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. Link [here](#).
- Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021. Link [here](#).
- COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021. Link [here](#).

# CDC Morbidity and Mortality Weekly Report Highlights

- In one [MMWR](#), a new CDC analysis found that getting a third dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna), either as an additional primary dose among immunocompromised people or as a booster dose, was highly effective at preventing COVID-19-associated emergency department or urgent care visits, and hospitalizations during both the Delta and Omicron predominant periods.
  - A third dose prevented COVID-19-associated emergency department or urgent care visits by 94% during Delta and 82% during Omicron circulation and prevented COVID-19-associated hospitalizations by 94% and 90%, respectively.
  - Vaccine effectiveness was higher in adults who were eligible for and received a third mRNA vaccine dose either as part of a primary vaccine series (immunocompromised) or as a booster dose, compared with those who had received 2 doses.
    - Vaccine effectiveness increased following a third dose during both the Delta- and Omicron-predominant periods.
- A second [MMWR](#) found that when Delta was the dominant variant, and in the initial days of Omicron, people who were fully vaccinated and boosted had the highest protection against infection.
- A study [published](#) in *JAMA* found that a third dose of a COVID-19 mRNA vaccine provides significant added protection against symptomatic COVID-19 disease caused by the Delta and Omicron variants.
  - Protection was greater against the Delta variant compared with the Omicron variant.
  - This is one of the first U.S. peer-reviewed studies assessing COVID-19 vaccine performance against the rapidly spreading Omicron variant, which is critical to inform public health guidance.





# CT Wiz/VAMS Update

# Upcoming CT WiZ & VAMS Enhancements & Office Hours and Helpdesk Support

# CT WiZ Enhancement

**February 7<sup>th</sup> CT WiZ release:** Enhancement will add '**Dose Level Accountability**' for CVP eligibility for each vaccine which will enable clinics to properly document both patient and dose level eligibility according to: [Connecticut's Vaccine Eligibility Criteria](#).

- Clinic's using CT WiZ User Interface/Direct Data Entry select the '**Patient Level Eligibility**' in the Demographics screen which will populate and default to the **Administer Vaccines** screen. After adding the vaccine(s), you can change a vaccine's eligibility at the dose level on this screen if needed (i.e. **COVID-19 vaccine will always be under 'VO1 Not VFC Eligible'**.)
- Clinics onboarded with their EHR will report eligibility the same way as now, as eligibility is sent with each dose and is populated at the dose level already.

**Coming in March CT WiZ release:** Enhancement will add pop-ups for users when entering to alert when certain eligibility status is selected (i.e., patient is over age 18 and they are not eligible for CVP vaccine.)

**Reminder:** CT WiZ is down from 8pm-10pm for these Monthly Releases.

# VAMS 7.0 Enhancements

- VAMS 7.0 is **planned for release** on Thursday, January 27<sup>th</sup>, 2022
- Enhancements below (will be deployed when this age group is approved):
  - Clinic Administrators at standard and mobile clinics can offer Pediatric Pfizer-BioNTech COVID-19 vaccine (**ages 2 – 4**) doses at their clinics
  - Utilize the Products Carried checkbox
  - Clinic Administrators in standard and mobile clinics can set a reservation tier age group to 2 – 4 years
- VAMS 7.1 – February 2022
  - Enhancements to Inventory components and reports

## Vaccine products carried (optional)

Use the checkboxes below to indicate which vaccine products and doses are being offered at your clinic location.

- Pfizer-BioNTech (COMIRNATY) COVID-19 Vaccine
  - 1st dose
  - 2nd dose
  - Booster dose
  - 1st dose Pediatric vaccine (ages 5-11)
  - 2nd dose Pediatric vaccine (ages 5-11)
  - 1st dose Pediatric vaccine (ages 2-4)
  - 2nd dose Pediatric vaccine (ages 2-4)



# VAMS to CT WiZ Transition Process

## Has your VAMS Clinic Transitioned to CT WiZ Yet?

Benefits of CT WiZ include:

- the consolidated record available to the provider for clinical decision support
- an official immunization record available to the patient in the Public Portal
- ability to electronically report from your EHR
- managing inventory in one system *if both CVP and CoVP*
- ability to run many reports



**If your clinic is using VAMS and wants to transition to CT WiZ to manage inventory and report COVID-19 vaccinations:**

- ❖ please [submit a helpdesk ticket](#) with your PIN and expected date of transition
- ❖ DPH will schedule a call to review the [transition process](#) with your clinic

# CT WiZ/VAMS Office Hours

## [CT WiZ/VAMS Live Helpdesk Office Hours](#)

Join Via Microsoft Teams

**Tuesdays 9:00am – 10:00am**

Join us anytime during office hours to ask a question!

\*If you can't join during this time, visit our [webpages](#) for training materials or our DPH Helpdesk to [submit a request](#).

# Question and Answers

To ask a question, please raise your hand using the hand icon on your screen, type your question in the chat box or if you are on the phone press \*6 to unmute yourself.

If you have additional questions after the meeting, please feel free to email them to [DPH.Immunizations@ct.gov](mailto:DPH.Immunizations@ct.gov)

You can fill out a help desk ticket by visiting <https://dph-cthelpdesk.ct.gov/Ticket>